VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has received Human Research Ethics Committee (HREC) approval from The Royal Melbourne Hospital.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has agreed revised terms with cornerstone investor Mr Aiden Jiang for the draw down of $1,500,000 from a previously agreed convertible loan facility.
VGI Health Technology Limited (NSX:VTL) is pleased to present the FY21 Annual Report to Shareholders.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that eminent hepatologist, Professor Darrell H.G. Crawford, has been appointed to its Scientific Advisory Board (SAB).
VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has appointed Gallipoli Medical Research Foundation (GMRF) as a clinical study site for Phase II Clinical Study.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that it's operational subsidiary, Invictus Ops Pty Ltd., has approved a clinical study protocol for a clinical study to be conducted by Altipure R&D in Ohio.
Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal health in humans and animals, invites shareholders to attend a virtual group briefing with Chief Executive Officer, Steven Lydeamore, on Thursday 9 September 2021 at 11:00am AEST.
